Search results for "Secondary Prevention"

showing 9 items of 119 documents

THE ROLE OF ENDOSCOPY IN ACUTE RECURRENT AND CHRONIC PANCREATITIS AND PANCREATIC CANCER

1999

Endoscopy plays an important role in the diagnosis and treatment of acute and chronic pancreatitis as well as pancreatic cancer. Sphincterotomy and stone removal in biliary pancreatitis, stone extraction and drainage in chronic pancreatitis, and stent implantation in pancreatic cancer are the predominant procedures. With endoscopy, minimal invasive techniques are at hand to solve urgent and long term problems.

medicine.medical_specialtyPancreatic diseaseCost-Benefit AnalysisGastroenterologyDiagnosis DifferentialPancreatic cancerInternal medicineSecondary PreventionmedicineHumansStone extractionEndoscopy Digestive Systemmedicine.diagnostic_testbusiness.industryGastroenterologymedicine.diseaseEndoscopyPancreatic NeoplasmsTreatment Outcomemedicine.anatomical_structurePancreatitisAcute DiseaseChronic DiseasePancreatitisStone removalNeoplasm Recurrence LocalDifferential diagnosisPancreasbusinessGastroenterology Clinics of North America
researchProduct

Comparing medical treatments for Crohn’s disease

2013

The drugs available for inflammatory bowel disease are aminosalicylates, antibiotics, steroids, immunosuppressors and biologics. The effectiveness of these drugs has been evaluated in many randomized clinical trials, mainly versus placebo. Few studies have been conducted comparing the different drugs among themselves, owing to the methodological problems raised by comparative trials, such as sample size and blindness. This review focuses mainly on the randomized clinical trials that have compared different treatments. Of course comparisons are mainly between drugs used in a particular setting (mild, moderate and severe disease). However, on many occasions there is no homogeneity in these cl…

medicine.medical_specialtyPathologymedicine.drug_classAntibioticsAlternative medicineSevere diseasePlaceboInflammatory bowel diseaselaw.inventionBiological FactorsCrohn DiseaseRandomized controlled trialAdrenal Cortex HormoneslawInternal medicineAzathioprineIntestinal FistulaSecondary PreventionmedicineHumansBudesonideRandomized Controlled Trials as TopicCrohn's diseasebusiness.industryProbioticsHealth Policymedicine.diseaseAnti-Bacterial AgentsAminosalicylic AcidsMethotrexateSample size determinationbusinessJournal of Comparative Effectiveness Research
researchProduct

0133: The Log Book as a new tool for the secondary prevention of coronary artery disease

2016

International audience; IntroductionThe Log book (LB) project was created by a multidisciplinary team of healthcare professionals from a regional care network and aimed to improve secondary prevention (SP) after acute myocardial infarction (MI) in Cote d’Or. LB includes information and advices for increasing self management of risk factors by the patient.MethodsA prospective interventional study on 469 patients hospitalised for an acute MI in the 2 Intensive Coronary Care unit of Côte d’Or (CHU Dijon and Clinique de Fontaine les Dijon) in 2012 and surviving at 1 year follow-up (FU). LB was randomly given at the time of their hospitalisation by the nursing team, also providing oral advices o…

medicine.medical_specialtyPediatrics030204 cardiovascular system & hematologyCoronary artery disease03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMedicine030212 general & internal medicineMyocardial infarctionRisk factorAcute miSecondary preventionSelf-managementbusiness.industryPrevention[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.disease3. Good healthMyocardial infarctionEmergency medicineCoronary care unitSelf careCardiology and Cardiovascular MedicinebusinessLog book
researchProduct

EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study

2021

Abstract Aims To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement. Methods and results An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis…

medicine.medical_specialtyRegistryStatinEpidemiologymedicine.drug_class030204 cardiovascular system & hematologyGuidelinesSecondary care03 medical and health sciences0302 clinical medicineEzetimibeRisk FactorsInternal medicinemedicineHumans030212 general & internal medicinePCSK9 InhibitorsDyslipidemiasSecondary preventionPrimary Health Carebusiness.industryAnticholesteremic AgentsStatinsCholesterol LDLGuidelineLipidsConfidence intervalCross-Sectional StudiesTreatment OutcomeCholesterolCardiovascular DiseasesObservational studyHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugDA VINCI study
researchProduct

One year after the ESC/EAS guidelines on cholesterol control. What's the new evidence? What's missing?

2021

The recent ESC/EAS 2019 Guidelines for the management of dyslipidaemias are centred on the causal role of low density lipoprotein (LDL), or more generally apolipoprotein B (apoB)-containing lipoproteins, in atherosclerosis as an essential principle. Despite updated goals and recommendations, that have further highlighted the importance of a powerful reduction in LDL-C levels to reduce the individual CV risk, some challenges remain to be addressed in view of future guideline elaboration. In this review, we will summarize the new evidence from clinical trials since 2019 guideline release and discuss the possible challenges for the future.

medicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BControl (management)Guidelinechemistry.chemical_compoundRisk FactorsCardiovascular DiseasePrimary preventionCardiovascular disease DyslipidemiaInternal MedicineHumansMedicineIntensive care medicineDyslipidemiasSecondary preventionPrimary preventionbiologybusiness.industryCholesterolSecondary preventionLDL-C treatmentCholesterol LDLGuidelineAtherosclerosisClinical trialCholesterolchemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Risk Factors: AtherosclerosiHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessEuropean Journal of Internal Medicine
researchProduct

Antiplatelets in stroke prevention

2014

Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both for the secondary prevention of stroke in patients with a history of non-cardioembolic st…

medicine.medical_specialtySettore MED/09 - Medicina InternaMEDLINEPrimary preventionSecondary PreventionmedicineAnimalsHumanscardiovascular diseasesMyocardial infarctionIntensive care medicineStrokeCause of deathPharmacologySecondary preventionAspirinAspirinbusiness.industrymedicine.diseasePrimary PreventionStrokeCardiovascular DiseasesPhysical therapyPlatelet aggregation inhibitorantiplatelets Stroke preventionCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Juvenile central ossifying fibroma of the mandible: a case report

2010

Central ossifying fibroma is a rare fibro-osseous neoplasm in young children. It is highly aggressive and has a strong tendency to recur. We describe an 11-year-old girl with juvenile central ossifying fibromas of the mandible that caused obstruction of tooth eruption of the lower left second premolar. Oral examination revealed the presence of the primary lower left second molar and a small bony hard swelling over the left side of the mandibular body. After a computed tomographic scan, an incisional biopsy was performed, and the lesion proved to be a juvenile ossifying fibroma. Although this tumor often recurs early, and many authors suggest radical en bloc resection, we performed a more co…

medicine.medical_specialtyTooth eruptionMandibular nerveMandibular NeoplasmsTooth EruptionSettore MED/29 - Chirurgia MaxillofaccialeLesionMandibular second molarmandiblestomatognathic systemSettore MED/28 - Malattie OdontostomatologichemedicinePremolarSecondary PreventionHumansBicuspidChildbusiness.industryCentral ossifying fibromaMandibleGeneral Medicinemedicine.diseaseSurgerystomatognathic diseasesMandibular Neoplasmsmedicine.anatomical_structureTreatment OutcomePediatrics Perinatology and Child HealthFibroma OssifyingCentral fibroma ossifyingSurgeryFemalemedicine.symptombusinessTomography X-Ray Computedteeth eruption
researchProduct

Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis.

2010

Long-term anticoagulant treatment is highly effective in preventing recurrent Venous Thrombo-Embolism (VTE) in patients with idiopathic Deep Vein Thrombosis (DVT) of the lower limbs, though associated with an increased risk for major bleeding that may offset the benefits of anticoagulation. Accordingly to recent guidelines, patients with idiopathic DVT should be treated for at least 3 months and then should be evaluated for the risk-benefit ratio of long-term therapy. However, such ‘time for decision’ is often unclear and the optimal duration of VKA remains debatable. In recent studies, markers for the assessment of the individual risk for recurrent thrombosis have been proposed, which can …

medicine.medical_specialtyVitamin Kmedicine.drug_classDeep veinDrug Administration ScheduleFibrin Fibrinogen Degradation ProductsRisk FactorsNeoplasmsDrug DiscoveryD-dimerSecondary PreventionHumansMedicineUltrasonographyVenous ThrombosisPharmacologyFirst episodebusiness.industryVascular diseaseAnticoagulantAnticoagulantsresidual vein thrombosis anticoagulant therapymedicine.diseaseThrombosisSurgeryVein thrombosisVenous thrombosismedicine.anatomical_structurebusiness
researchProduct

Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?

2013

""The primary aim of the study was to analyze the endometrioma recurrence rate in patients who underwent laparoscopic excision followed by postoperative long-term regimen of oral contraceptives (OCs).. . MATERIALS AND METHODS: 168 patients who underwent a conservative laparoscopic surgery for endometrioma, during the period between September 2009 and August 2010 in three university hospitals were studied. A long-term OCs therapy was offered to all women following surgery. Patients were randomly divided into three groups according to different progestins used (desogestrel, gestodene, dienogest). Women who refused a postoperative hormonal therapy served as control. Follow-up visits and transv…

minimally invasive gynecologic surgeryAdultmedicine.medical_specialtyEndometriosis endometrioma recurrencee oral contraceptives minimally invasive gynecologic surgery progestins dienogest.AdolescentNorpregnenesendometrioma recurrenceeEndometriosisEndometriosisKaplan-Meier EstimateDrug Administration Schedulelaw.inventionYoung Adultchemistry.chemical_compoundRandomized controlled triallawSecondary PreventionHumansNandroloneMedicineIn patientOvarian DiseasesYoung adultLaparoscopyoral contraceptivesDesogestrelmedicine.diagnostic_testbusiness.industryObstetricsObstetrics and GynecologyEndometriosis Endometrioma recurrence Oral contraceptives Minimally invasive gynaecologic surgery Progestins DienogestGeneral MedicineLaparoscopic excisionmedicine.diseaseCombined Modality TherapySurgeryRegimenTreatment OutcomeDienogestchemistryprogestinsdienogestFemaleLaparoscopybusinessContraceptives OralFollow-Up Studies
researchProduct